AstraZeneca (BUE:AZN) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:AZN AstraZeneca PLC BUE:AZN
79 GF Score
Price ARS66,700.00
GF Value ARS71,271.93
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

BUE:AZN
79GF Score
AstraZeneca PLC BUE:AZN
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (BUE:AZN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of ARS66,700.00 is trading 6.4% below its estimated GF Value™ of ARS71,271.93. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for BUE:AZN:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: ARS71,271.93 vs. price of ARS66,700.00 (6.4% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the BUE:AZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
79GF Score

Get the complete analysis for BUE:AZN

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS66,700.00
Price
ARS71,271.93
GF Value